Levosimendan compared with dobutamine in low output patients

Minerva Anestesiologica

Volumn 69, Issue 4, 2003, Pages 258-263

  Nieminen, M S ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cardiac output; Dobutamine; Heart failure, congestive; Levosimendan

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOBUTAMINE; LEVOSIMENDAN; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FORWARD HEART FAILURE; HEART ARRHYTHMIA; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEMODYNAMICS; HUMAN; MORTALITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; COMPARATIVE STUDY; LUNG WEDGE PRESSURE; PATHOPHYSIOLOGY;

CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; DOBUTAMINE; DOUBLE-BLIND METHOD; HEMODYNAMIC PROCESSES; HUMANS; HYDRAZONES; PULMONARY WEDGE PRESSURE; PYRIDAZINES;

EID: 0141724848     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Cleland JG, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Fail 1999;1:229-41.
2. McMurray J, McDonagh T, Morrison CE, Dargie HJ. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J 1993;14:1158-62
3. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Lindén I-B. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-66.
4. Haikala H, Linden IB. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 1995; 26(Suppl 1):10-9.
5. Levijoki J, Pollesello P, Kaivola J, Tilgmann C, Sorsa T, Annila A et al. Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol 2000;32:479-91.
6. Pollesello P, Ovaska M, Kaivola J, Tilgmann C, Lundström K, Kalkkinen N et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 1994;269(46):28584- 28590.
7. Sorsa T, Heikkinen S, Abbott MB, Abusamhadneh E, Laakso T, Tilgmann C et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 2001;76:9337-43.
8. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide- sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997;333:249-59.
9. Follath F, Cleland JG, Just H, Papp JG, Scholz H. Efficacy and safety of intravenous levosimendan in severe low-output heart failure. A randomized, double-blind comparison to dobutamine (The LIDO study). Orion Pharmaceutica clinical study report. Report No. 3001021b. 8-8-2000.
10. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-12.
11. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222-7.
12. Singh BN, Lilleberg J, Sandell E-P, Ylonen V, Lehtonen L, Toivonen L. Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure. Am J Cardiol 1999;83:16-20.
13. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998;19:660-8.
14. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999;34:219-28.